ACTIMMUNE significantly reduced the total number of serious infections* in patients with CGD1,2

Graph showing that ACTIMMUNE® (Interferon gamma-1b) reduced the total number of infections by 64% compared to placebo

Graph showing that ACTIMMUNE® (Interferon gamma-1b) reduced the total number of infections by 64% compared to placebo

Most patients in the clinical trial also received prophylactic antibiotics.

ACTIMMUNE significantly reduced risk of serious infections* in patients with CGD1,2

Treatment effect of ACTIMMUNE is seen early and maintained for the duration of the study.

Graph showing 67% reduction in relative risk of serious infections for CGD patients receiving ACTIMMUNE® (Interferon gamma-1b) compared to placebo

Graph showing 67% reduction in relative risk of serious infections for CGD patients receiving ACTIMMUNE® (Interferon gamma-1b) compared to placebo

ACTIMMUNE delivers efficacy across various patient types

In subgroup analyses, ACTIMMUNE was beneficial regardless of age or type of CGD inheritance.1,2

Graph showing ACTIMMUNE® (Interferon gamma-1b) clinical trial efficacy for CGD patients younger than 10 years, with RR = 4.84 compared to placeboGraph showing ACTIMMUNE® (Interferon gamma-1b) clinical trial efficacy for CGD patients younger than 10 years, with RR = 4.84 compared to placebo

Graph showing ACTIMMUNE® (Interferon gamma-1b) clinical trial efficacy for X-linked CGD patients, with RR = 3.38 compared to placeboGraph showing ACTIMMUNE® (Interferon gamma-1b) clinical trial efficacy for X-linked CGD patients, with RR = 3.38 compared to placebo

Graph showing ACTIMMUNE® (Interferon gamma-1b) clinical trial efficacy for CGD patients older than 10 years, with RR = 2.14 compared to placeboGraph showing ACTIMMUNE® (Interferon gamma-1b) clinical trial efficacy for CGD patients older than 10 years, with RR = 2.14 compared to placebo

Graph showing ACTIMMUNE® (Interferon gamma-1b) clinical trial efficacy for autosomal recessive CGD patients, with RR = 2.32 compared to placeboGraph showing ACTIMMUNE® (Interferon gamma-1b) clinical trial efficacy for autosomal recessive CGD patients, with RR = 2.32 compared to placebo

§Not statistically significant; P > 0.05

ACTIMMUNE significantly reduced inpatient hospitalization days compared with placebo1,2

Treatment with ACTIMMUNE resulted in 33% shorter average length of stay in patients who did need to be hospitalized†

†32 days in the ACTIMMUNE group vs 48 days in the placebo group; P = 0.02.

Graph of clinical trial patients taking ACTIMMUNE® (Interferon gamma-1b) experienced 67% fewer hospitalization days compared to patients taking a placebo

Graph of clinical trial patients taking ACTIMMUNE® (Interferon gamma-1b) experienced 67% fewer hospitalization days compared to patients taking a placebo

ACTIMMUNE helped keep patients free of serious infections for up to 12 months2

More than twice as many patients treated with ACTIMMUNE remained free of serious infection for up to 12 months compared with patients treated with placebo.

77%

were free of serious infection for up to the 12 months of the study‡

Compared to

30%

of patients who received placebo (P = .0006)

*Serious infection was defined as a clinical event requiring hospitalization and intravenous antibiotics.

‡Mean duration of ACTIMMUNE treatment was 8.9 months.

Download the patient
enrollment form
Review X-linked CGD
case studies

References: 1. ACTIMMUNE® (Interferon gamma-1b) [prescribing information] Horizon. 2. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991;324(8):509-516.

Approved Uses and Important Safety Information

INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • In patients who develop or have known hypersensitivity to interferon-gamma, E. coli derived products, or any component of the product

WARNINGS AND PRECAUTIONS

  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year
  • Monitoring:
    • Patients begun on ACTIMMUNE before age 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE
  • Pregnancy, Lactation, and Fertility:
    • ACTIMMUNE should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus
    • Use of ACTIMMUNE by lactating mothers is not recommended. ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the mother
    • Long-term effects of ACTIMMUNE on fertility are not known

DRUG INTERACTIONS

  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness

Approved Uses and Important Safety Information

INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • In patients who develop or have known hypersensitivity to interferon-gamma, E. coli derived products, or any component of the product

WARNINGS AND PRECAUTIONS

  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year
  • Monitoring:
    • Patients begun on ACTIMMUNE before age 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE
  • Pregnancy, Lactation, and Fertility:
    • ACTIMMUNE should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus
    • Use of ACTIMMUNE by lactating mothers is not recommended. ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the mother
    • Long-term effects of ACTIMMUNE on fertility are not known

DRUG INTERACTIONS

  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness